Specificity and Personalized medicine: a novel approach to Cancer management

Authors

1. Irfat Ara
   Research officer, Regional Research Institute of Unani Medicine, Srinagar, Jammu and Kashmir, India
2. Mudasir Maqbool
   Research Scholar, Department of Pharmaceutical Sciences, University of Kashmir, Srinagar, Jammu and Kashmir, India
3. Imran Gani
   Research Scholar, Department of Pharmaceutical Sciences, University of Kashmir, Srinagar, Jammu and Kashmir, India

Abstract

With the advent of precision and personalized medicine (PPM), medical care may now be adapted to each patient's unique needs. Among the top causes of death in India is cancer. Maximum chemotherapeutic treatments are utilized for cancer patients, despite the lack of long-term effectiveness and significant side effects from these agents. To improve therapeutic success, a new tool called PPM was developed. Insights into pharmacogenomics have aided in the development of and the possibility for individualized cancer treatment. In modern PPM, genetic or other information on a particular patient is used systematically to select or optimize preventative and therapeutic therapy for that patient. Knowledge of a patient's protein, genetic, and metabolic profile can help doctors give them the best possible care. The development of companion diagnostics, in which molecular assays measuring levels of proteins, genes, or specific mutations are used to stratify disease status, pick the appropriate drug, and tune dosages there, is a central feature of this medical strategy. As a result, recent breakthroughs in oncology have piqued interest in the field as a whole, prompting calls for greater emphasis on the role of the oncology department or health care system in the quest for greater accuracy and individualization. In this article, we will examine the state of the art and discuss potential future developments that could help expedite the creation of PPM medicines for the treatment of cancer that has become resistant to standard therapies in individual patients. The focus will be on the phenotypic (activity-based) rather than the genotypic (mechanism-based) approach to PPM development, and how it can benefit cancer patients. The path to precise and individualized treatment has been opened by the article's perspective, in which focus is placed on the specific modifications of the tumor.

Keywords

Cancer, Personalized medicine, therapeutic outcome, tumor.

Full Text

HTML full text is not available. Refer to the PDF galley.